11 Apr. 2019
REVIVING A DRUG FOR TUBERCULOSIS ?
A compound called SMARt-420 renders ethionamide-resistant strains of Mycobacterium tuberculosis fully susceptible.
11 Apr. 2019
WHO UPDATES ESSENTIAL MEDICINES LIST WITH NEW ADVICE ON THE USE OF ABS....
New advice on which antibiotics to use for common infections and which to preserve for the most serious circumstances is among the additions to the WH...
11 Apr. 2019
BEOBACHTER 10/2017: DIE TUBERKULOSE ÜBERLISTET. EIN INTERVIEW MIT MARC GITZINGER
Tuberkulose-Erreger sind zunehmend unempflindlich gegen Antibiotika. "Wir in der Schweiz können nicht sagen, Tuberkulose ginge uns nichts an" Marc...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
